A New Clinical Research Study for Duchenne Muscular Dystrophy and the Heart: The THRIVE-2 Study

THRIVE-2 is a Phase 2 clinical research study of an investigational therapy for people with Duchenne (DMD) and heart involvement. See who may join.

L.A Hernandez

11/17/20263 min read

A New Clinical Research Study for Duchenne and the Heart: The THRIVE-2 Study

Learn about a Phase 2 clinical research study for people living with Duchenne muscular dystrophy and heart involvement.

At the Neurology Rare Disease Center, we believe families should have clear, simple information about clinical research. Today we want to share a clinical research study called THRIVE-2. It is studying an investigational therapy called STM-01 in people with Duchenne muscular dystrophy (DMD) who also have heart involvement.

Below you will find the main facts in plain language. If you have questions, our team is here to help.

What is Duchenne muscular dystrophy (DMD)?

Duchenne muscular dystrophy is a rare, progressive, X-linked genetic condition caused by changes (mutations) in the gene that makes a protein called dystrophin. Over time, DMD affects the muscles of the body, including the heart.

Why does the heart matter in DMD?

The heart is a muscle too. In people with DMD, the heart muscle can also be affected over time. This is called DMD-associated cardiomyopathy, and it is recognized as a leading cause of death in people with DMD. Researchers are still working to find better ways to address it, and that is one reason clinical research in this area is important.

What is the THRIVE-2 study?

THRIVE-2 is a Phase 2 clinical research study. It is designed to learn about the safety and the potential effectiveness of STM-01 in people with DMD who have heart involvement. The study is open-label, which means participants and the study team know that everyone receives the study therapy.

Researchers will look at changes in:

  • Heart function

  • Upper limb strength and mobility

  • Quality of life

  • Overall safety

What is STM-01?

STM-01 is an investigational therapy. It is made from neonatal cardiac progenitor cells, which are heart-derived cells. According to the study sponsor, Secretome Therapeutics, it is designed to use the "secretome" of these cells, which is a group of biologically active substances that have been associated with calming inflammation and reducing scarring (fibrosis) in laboratory research.

Whether STM-01 is safe and whether it can help people with DMD is exactly what this study is meant to find out.

What does "investigational" mean?

"Investigational" means that STM-01 is still being studied in clinical research and has not been approved by any health authority for sale or general use, including the U.S. Food and Drug Administration (FDA). Taking part in a study does not guarantee any benefit.

Who may be able to take part?

THRIVE-2 is looking for participants who:

  • Are male, 8 years of age or older

  • Have genetically confirmed Duchenne muscular dystrophy (DMD)

  • Show evidence of heart (cardiac) involvement

Other eligibility criteria will apply. The study team will review everything with you and your child's doctor. Final eligibility details will be listed on ClinicalTrials.gov.

What will participation look like?

If a participant qualifies and the family decides to join, participants will receive intravenous (IV) infusions of STM-01 every six weeks over an 18-month period. During the study, the research team will carefully follow each participant's heart function, upper limb strength and mobility, quality of life, and safety.

Joining a study is always a choice, and families can ask questions at any time, before and during the study.

What are the costs to take part?

[CONFIRM WITH SPONSOR / IRB-APPROVED INFORMED CONSENT BEFORE PUBLISHING. Do not add any statement about costs, payment, or travel reimbursement until the sponsor approves the wording.]

Why do clinical research studies matter?

Clinical research studies are how doctors and scientists learn whether an investigational therapy is safe and whether it works. Before any therapy can be approved and made available to the public, it must go through several phases of research. People take part in studies for many reasons. Some want to learn more about their condition. Others want to help researchers learn more so that future patients may benefit. Joining a study is always your choice.

How can I learn more?

Other eligibility criteria will apply.

The investigational therapy STM-01 has not been approved by the U.S. Food and Drug Administration (FDA) or any other health authority. This page is for information only and is not medical advice. Taking part in a clinical research study does not guarantee any benefit.